ArticleEuropean journal of medical research2022

A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.

Ann W Silk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.